WELL-ESTABLISHED SAFETY PROFILE

Most common ARs (≥20%) with a ≥5% higher incidence for ABRAXANE/gemcitabine arm
Most common adverse reactions of the MPACT trial Most common adverse reactions of the MPACT trial
  • ABRAXANE + gemcitabine had the same incidence of death due to adverse reactions compared to gemcitabine alone (4% of patients in each arm)2
  • Disease progression was the most common reason for treatment discontinuation2
  • The most common ARs resulting in permanent discontinuation of ABRAXANE were:
    8% peripheral neuropathy | 4% fatigue | 2% thrombocytopenia
    The most common ARs resulting in permanent discontinuation of ABRAXANE were: 8% peripheral neuropathy | 4% fatigue | 2% thrombocytopenia
  • Selected Adverse Reactions

    WELL-ESTABLISHED SAFETY PROFILE

    Higher incidence (≥5% for all grade toxicity or ≥2% Grade 3 or higher toxicity)
    in the ABRAXANE + gemcitabine arm
    CLOSE THE TAB
  • Most Serious Adverse Reactions

    WELL-ESTABLISHED SAFETY PROFILE

    Most common serious ARs (with a ≥1% higher incidence) for ABRAXANE + gemcitabine arm Most common serious ARs (with a ≥1% higher incidence) for ABRAXANE
    + gemcitabine arm
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL